← Eichor
Study identifier: NCT02423395 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis

Condition: Liver Cirrhosis · Muscle Cramps  ·  Sponsor: Sherief Abd-Elsalam

PhasePhase 3
Planned participants100
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Muscle cramps are common in patients with liver disease and associated with significantly diminished quality of life. Patients with cirrhosis often experience muscle cramps with varied frequency and severity. The exact mechanisms by which they occur remain unclear, although a number of pathophysiological events unique to liver disease may contribute. Clinical studies have identified alterations in 3 areas: nerve function, energy metabolism, and plasma volume/electrolytes (1) Orphenadrine is an anticholinergic drug with prominent central nervous system (CNS) and peripheral actions used to treat painful muscle spasms and other similar conditions. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including from: radiculopathy, muscles, and headaches. \[3,4\]

This description comes directly from the study's public registry record.

Talk to the study team

Sherief M Abd-Elsalam, lecturer  ·  01000058842  ·  Sherif_tropical@yahoo.com

Always discuss trial participation with your own doctor first.

Locations (1)

Tanta university hospitalTanta, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02423395